Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q12834
UPID:
CDC20_HUMAN
Alternative names:
p55CDC
Alternative UPACC:
Q12834; B2R6Z6; D3DPJ1; Q5JUY4; Q9BW56; Q9UQI9
Background:
Cell division cycle protein 20 homolog (CDC20) plays a pivotal role in cell cycle regulation. It is essential for the ubiquitin ligase activity of the anaphase promoting complex/cyclosome (APC/C), influencing substrate specificity and ensuring proper cell division. CDC20's activity is modulated by MAD2L1, with the CDC20-APC/C complex being inactive in metaphase and active in anaphase, targeting specific substrates for degradation. Additionally, CDC20 is involved in synaptic vesicle clustering in neurons, indicating its role beyond cell division.
Therapeutic significance:
Understanding the role of Cell division cycle protein 20 homolog could open doors to potential therapeutic strategies.